Latest News Archive
Please select Category, Year, and then Month to display items
21 June 2019
|
Story Lacea Loader
The University of the Free State (UFS) will be presenting the 2nd UFS Thought-Leader Series in cooperation with Vrye Weekblad as part of the Vrystaat Arts Festival.
Facilitator: Dr Max du Preez, Editor of Vrye Weekblad
Thursday 4 July 2019
Economic and Management Sciences Auditorium, UFS Bloemfontein Campus.
Two panel discussions will take place:
10:00
Panel 1:
How can we fix the South African economy and create jobs?
12:00
Panel 2:
How can we establish a pro-youth and entrepreneurship strategy for South Africa?
Panellists include:
Mr Prince Mashele, Executive Director at the Centre for Politics and Research, political commentator
Ms Annabel Bishop, Chief Economist: Investec
Prof Philippe Burger, Vice-Dean (Strategic Projects):Faculty of Economic and Management
Sciences, UFS
Mr Dawie Roodt, Chief Economist, Efficient Group
Ms Maryana Iskander, Chief Executive Officer of Harambee Youth Employment Accelerator
Mr David Abbey, Rand Merchant Bank
Prof Brownhilder Neneh, Head: Department of Business Management, UFS
Attendance is free of charge.
Enquiries: news@ufs.ac.za | +27 51 401 3422.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004